查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1947838

AR T細胞療法市場分析及預測（至2035年）：按類型、產品類型、服務、技術、應用、最終用戶、流程、實施、階段和解決方案分類

AR T-Cell therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 349 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

抗原受體（AR）T細胞療法市場預計將從2024年的48億美元成長到2034年的368億美元，複合年成長率約為33%。 AR T細胞療法市場涵蓋了利用抗原受體進行精準標靶化的先進免疫療法，這些療法透過改造T細胞來識別並攻擊癌細胞。基因工程和個人化醫療領域的創新是推動該市場成長的主要動力，旨在提高治療效果並降低復發率。癌症發病率的上升和生物技術領域投資的增加正在推動市場成長，而重點在於拓展適應症和提高安全性。

受個人化醫療和免疫療法發展趨勢的推動，AR T細胞療法市場正經歷強勁成長。腫瘤領域是成長最快的領域，這主要得益於癌症發生率的上升和對標靶治療需求的不斷成長。在腫瘤領域，白血病和淋巴瘤等骨髓惡性腫瘤佔據了主要細分市場，並受益於其高療效。固體癌目前處於次要地位，但隨著研究的進展和現有挑戰的克服，其成長勢頭正在增強。非腫瘤領域，主要關注自體免疫疾病和感染疾病，是成長第二快的領域。 T細胞工程和擴增技術的創新正在提高療效和安全性。尤其是在多發性硬化症和類風濕性關節炎等自體免疫疾病方面，已展現出令人鼓舞的成果，促使更多投資湧入。感染疾病領域，主要關注病毒感染疾病，也是AR T細胞療法的一個極具潛力的應用領域。策略聯盟和不斷增加的臨床試驗正在加速市場發展，為相關人員提供了盈利的機會。

市場區隔
按類型 自體T細胞療法、異體T細胞療法
產品 CAR-T細胞療法、TIL（腫瘤浸潤淋巴細胞）療法、TCR（T細胞受體）療法
服務 臨床試驗服務、生產製造服務、物流與供應鏈服務、諮詢服務
科技 基因編輯、CRISPR、慢病毒載體、逆轉錄病毒載體
應用領域 腫瘤學、血液學、固態腫瘤、感染疾病
最終用戶 醫院、癌症研究機構、生物製藥公司、學術研究機構
過程 細胞分離、細胞活化、基因修飾、細胞增殖
實施表格 內部、外包
步 研究、臨床試驗和商業化
解決方案 個人化醫療，現成產品

AR T細胞療法市場呈現動態變化的格局，市佔率多元化，定價策略競爭激烈，新產品層出不窮。主要企業正利用創新方法拓展市場佔有率，同時保持價格競爭力，確保產品的可及性和市場滲透率。新型治療方法的推出推動了市場成長，各公司優先考慮策略性產品發布，以最大限度地擴大其影響力。這種不斷變化的市場格局凸顯了市場致力於推動治療方案、滿足未被滿足的醫療需求的努力。競爭基準分析顯示，主要企業透過策略聯盟和併購爭奪主導，競爭異常激烈。監管影響至關重要，嚴格的指導方針影響市場准入和研發時間表。美國和歐洲仍處於領先地位，制定的監管標準塑造全球市場格局。然而，新興市場及其不斷發展的法規結構蘊藏著尚未開發的機會。在技​​術進步和研發投入不斷增加的推動下，該市場蓄勢待發，即將迎來成長。

主要趨勢和促進因素：

受生物技術和個人化醫療進步的推動，AR T細胞療法市場正經歷強勁成長。一個關鍵趨勢是，人們越來越關注根據個別患者情況量身定做的精準醫療，以提高治療效果並最大限度地減少副作用。基因工程和合成生物學的突破性進展為這一趨勢提供了支持，使更具針對性和有效性的治療方法成為可能。癌症和其他慢性疾病的日益普遍是推動市場成長的關鍵因素，促使人們對AR T細胞療法等創新治療方法的需求不斷成長。此外，監管機構認知到這些療法在滿足未被滿足的醫療需求方面的潛力，正在積極推動加快核准流程。這種監管支持營造了有利於快速創新和商業化的環境。對研發的投資也是一個關鍵促進因素，公共和私營部門都投入了大量資源用於AR T細胞療法計劃。生物技術公司與學術機構之間的合作正在加速發現和開發的步伐。此外，新興市場不斷擴大的醫療基礎設施正在開闢新的市場進入途徑，為那些能夠滿足日益成長的先進治療解決方案需求的公司提供了盈利機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 自體T細胞療法
    • 同種異體T細胞療法
  • 市場規模及預測：依產品分類
    • CAR T 細胞
    • 腫瘤浸潤淋巴細胞（TILs）
    • TCR（T細胞受體）療法
  • 市場規模及預測：依服務分類
    • 臨床試驗服務
    • 製造服務
    • 物流和供應鏈服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 基因編輯
    • CRISPR
    • 慢病毒載體
    • 逆轉錄病毒載體
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 血液學
    • 固態腫瘤
    • 感染疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究所
    • 生物製藥公司
    • 學術研究機構
  • 市場規模及預測：依製程分類
    • 細胞分離
    • 細胞活化
    • 基因改造
    • 細胞增殖
  • 市場規模及預測：依發展狀況
    • 內部
    • 外包
  • 市場規模及預測：依階段分類
    • 調查
    • 臨床試驗
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 個人化醫療
    • 現成產品

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Adaptimmune Therapeutics
  • Atara Biotherapeutics
  • Autolus Therapeutics
  • Bellicum Pharmaceuticals
  • Cellectis
  • Celyad Oncology
  • Fate Therapeutics
  • Genocea Biosciences
  • Iovance Biotherapeutics
  • Kiadis Pharma
  • Kite Pharma
  • Marker Therapeutics
  • Mustang Bio
  • Poseida Therapeutics
  • Precision Bio Sciences
  • Sorrento Therapeutics
  • Tessa Therapeutics
  • Tmunity Therapeutics
  • Triumvira Immunologics
  • ZIOPHARM Oncology

第9章：關於我們

簡介目錄
Product Code: GIS31609

AR T-Cell therapy Market is anticipated to expand from $4.8 billion in 2024 to $36.8 billion by 2034, growing at a CAGR of approximately 33%. The AR T-Cell Therapy Market encompasses advanced immunotherapies that engineer T-cells to recognize and attack cancer cells, leveraging antigen receptors for precision targeting. This market is driven by innovations in genetic engineering and personalized medicine, aiming to enhance treatment efficacy and reduce relapse rates. Rising cancer prevalence and increasing investment in biotechnology are propelling growth, with a focus on expanding indications and improving safety profiles.

The AR T-Cell Therapy Market is experiencing robust growth, fueled by advancements in personalized medicine and immunotherapy. The oncology segment is the top performer, driven by the increasing prevalence of cancer and the need for targeted therapies. Within oncology, hematologic malignancies such as leukemia and lymphoma are leading sub-segments, benefiting from high efficacy rates. Solid tumors, although currently secondary, are gaining momentum as research overcomes existing challenges. The non-oncology segment, focusing on autoimmune diseases and infectious diseases, is the second-highest performing area. Innovations in T-cell engineering and expansion techniques are enhancing efficacy and safety profiles. Autoimmune disorders, particularly multiple sclerosis and rheumatoid arthritis, are showing promising results, spurring further investment. The infectious disease sub-segment, with a focus on viral infections, is also emerging as a viable area for AR T-Cell applications. Strategic collaborations and increasing clinical trials are accelerating market evolution, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeAutologous T-Cell Therapy, Allogeneic T-Cell Therapy
ProductCAR T-Cells, TILs (Tumor Infiltrating Lymphocytes), TCR (T-Cell Receptor) Therapy
ServicesClinical Trial Services, Manufacturing Services, Logistics and Supply Chain Services, Consulting Services
TechnologyGene Editing, CRISPR, Lentiviral Vectors, Retroviral Vectors
ApplicationOncology, Hematology, Solid Tumors, Infectious Diseases
End UserHospitals, Cancer Research Institutes, Biopharmaceutical Companies, Academic and Research Institutes
ProcessCell Isolation, Cell Activation, Gene Modification, Cell Expansion
DeploymentIn-house, Outsourced
StageResearch, Clinical Trials, Commercialization
SolutionsPersonalized Medicine, Off-the-shelf Products

The AR T-Cell therapy market is characterized by a dynamic landscape featuring diverse market shares, competitive pricing strategies, and a surge in new product launches. Key players are leveraging innovative approaches to capture market share, while pricing remains competitive to ensure accessibility and market penetration. The introduction of novel therapies has invigorated the market, with companies prioritizing strategic launches to maximize impact. This evolving scenario underscores the market's commitment to advancing therapeutic options and meeting unmet medical needs. Competition benchmarking reveals a robust rivalry, with leading firms vying for dominance through strategic alliances and mergers. Regulatory influences play a pivotal role, with stringent guidelines impacting market entry and development timelines. The United States and Europe remain at the forefront, setting regulatory standards that shape global market dynamics. Emerging markets, however, present untapped opportunities, as regulatory frameworks evolve. The market is poised for growth, driven by technological advancements and increased investment in research and development.

Geographical Overview:

The AR T-Cell therapy market is witnessing substantial growth across various regions, each exhibiting unique dynamics. North America leads, propelled by robust research and development activities and significant healthcare investments. The presence of leading biotech firms and advanced healthcare infrastructure further accelerates market expansion. Europe follows closely, with strong government support and funding for innovative therapies fostering a conducive environment. The region's focus on personalized medicine and advanced healthcare solutions enhances its market potential. In Asia Pacific, the market is rapidly growing, driven by increasing healthcare expenditures and rising awareness of advanced therapies. Countries like China and India are emerging as key players, with substantial investments in biotechnology research. Latin America and the Middle East & Africa show promising growth potential. Latin America benefits from rising healthcare investments, while the Middle East & Africa are recognizing the importance of innovative therapies in addressing unmet medical needs and driving healthcare advancements.

The AR T-Cell therapy market is increasingly influenced by global tariffs and geopolitical dynamics, particularly in East Asia. Japan and South Korea are navigating US-China trade tensions by fostering domestic biotech innovation and enhancing cross-border collaborations. China's strategic pivot towards self-reliance in biopharma is evident in its increased R&D investments and regulatory reforms. Taiwan, while a hub for semiconductor manufacturing, is diversifying into biotech to mitigate geopolitical risks. The parent market is experiencing robust growth, driven by advancements in personalized medicine and increasing cancer prevalence. By 2035, the market is anticipated to mature through regional partnerships and technological breakthroughs. Meanwhile, Middle East conflicts contribute to volatile energy prices, indirectly affecting global supply chain costs and operational efficiencies in the biopharma sector.

Key Trends and Drivers:

The AR T-Cell therapy market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. A key trend is the increasing focus on precision therapies tailored to individual patient profiles, enhancing treatment efficacy and minimizing adverse effects. This trend is supported by breakthroughs in genetic engineering and synthetic biology, enabling more targeted and effective therapies. The growing prevalence of cancer and other chronic diseases is a significant driver, propelling the demand for innovative treatment options like AR T-Cell therapies. Additionally, regulatory agencies are increasingly facilitating accelerated approval pathways, recognizing the potential of these therapies to address unmet medical needs. This regulatory support is fostering an environment conducive to rapid innovation and commercialization. Investment in research and development is another critical driver, with both public and private sectors channeling substantial resources into AR T-Cell therapy projects. Collaborations between biotech companies and academic institutions are accelerating the pace of discovery and development. Furthermore, the expanding healthcare infrastructure in emerging markets is opening new avenues for market penetration, presenting lucrative opportunities for companies poised to meet the growing demand for advanced therapeutic solutions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous T-Cell Therapy
    • 4.1.2 Allogeneic T-Cell Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CAR T-Cells
    • 4.2.2 TILs (Tumor Infiltrating Lymphocytes)
    • 4.2.3 TCR (T-Cell Receptor) Therapy
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trial Services
    • 4.3.2 Manufacturing Services
    • 4.3.3 Logistics and Supply Chain Services
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 CRISPR
    • 4.4.3 Lentiviral Vectors
    • 4.4.4 Retroviral Vectors
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Hematology
    • 4.5.3 Solid Tumors
    • 4.5.4 Infectious Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Institutes
    • 4.6.3 Biopharmaceutical Companies
    • 4.6.4 Academic and Research Institutes
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Cell Isolation
    • 4.7.2 Cell Activation
    • 4.7.3 Gene Modification
    • 4.7.4 Cell Expansion
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Research
    • 4.9.2 Clinical Trials
    • 4.9.3 Commercialization
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Personalized Medicine
    • 4.10.2 Off-the-shelf Products

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atara Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Autolus Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bellicum Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Cellectis
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Celyad Oncology
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fate Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genocea Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Kiadis Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Kite Pharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Marker Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Mustang Bio
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Poseida Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Precision Bio Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Sorrento Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Tessa Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tmunity Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Triumvira Immunologics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 ZIOPHARM Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us